MONTREAL, QC / ACCESSWIRE / November 24, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it is pushing ahead with its Anti-Coronavirus drug development program. While the recent announcements about effective vaccines on the horizon is a cause for celebration, Sunshine Biopharma believes that a treatment for Coronavirus infections continues to be essential for any robust healthcare system. This is particularly important in view of the fact that gaps and lapses will likely occur during vaccine implementation and people may fall ill and require treatment. In addition, a treatment that can be taken orally at home, much like an antibiotic, would be an ideal complement for vaccination.

'SARS-CoV-2, the causative agent of COVID-19, is the third in a line of Betacoronaviruses that have caused serious human health threats in the past. The first two were SARS-CoV that appeared in 2002 and MERS-CoV in 2015,' said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. 'There is nothing that says that another Betacoronavirus with a potential for causing yet another serious threat to human health won't appear in the future. It is critical for us to have a treatment for today and as part of our preparedness for the future,' he added.

About Sunshine Biopharma's Coronavirus Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current ongoing pandemic that has claimed the lives of over 1.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness. Sunshine Biopharma has since screened the library and identified a lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture testing stage and assessment in Coronavirus infected mice before entering human clinical trials.

About Sunshine Biopharma

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:

Sunshine Biopharma, Inc.

Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.